Cartagenia, a Leuven, Belgium-, and Cambridge, MA-based provider of clinical-grade solutions for genomic assay interpretation and lab reporting to diagnostic genetics labs, clinicians and hospitals, closed a $5.9m (€4.25m) financing round.
Backers included existing shareholders Capricorn ICT Arkiv, the Flemish investment company PMV and Gemma Frisius Fund, the venture fund of the University of Leuven, as well as member of the management team.
The company intends to use the funds to expand its efforts to commercialize the Cartagenia Bench platform in key markets including North America and Europe as well as to extend its product portfolio in Oncology and Reproductive Health.
Led by Herman Verrelst, CEO, Cartagenia provides the Bench Lab, a medical device Software-as-a-Service solution designed for interpretation support, lab reporting, and data sharing for clinical genetic testing applications. Supported clinical applications of NGS, Sanger and array testing include constitutional and rare disease, prenatal diagnosis and screening, and germline and somatic oncology assays.
The suite is complemented with solutions for electronic assay requisition and lab reporting to referrers through Bench Portal, and tools for integrating it with hospital and lab informatics, such as LIMS and EHR systems.
The company currently serves more than 120 labs and clinics across North America, Europe and Australia.